Global Leuprolide Acetate Market Size, Share, Forecast Report, 2020-2027

Leuprolide is a synthetic nonapeptide acetate salt and is analogous to the gonadotropin-releasing hormone. The salt shows a therapeutic effect by binding to the receptors of the gonadotropin-releasing hormone. Leuprolide acetate is widely used as a therapeutic agent for the treatment of prostate cancer in men and precocious and uterine fibroids in women. Upset stomach, breast swelling, vaginal bleeding, impotence, and others are some of the major side effects associated with the use of this salt. The increasing prevalence of prostate cancer and the uterine fibroid is expected to be a major driver for the market growth during the forecast period. In 2015, according to the World Cancer Research Fund International, approximately 1.1 million cases of prostate cancer were recorded in 2014, accounting for ~8% of all the new cancer cases. Moreover, according to a study published in the BMC Women's Health Journal in 2012, the self-reported prevalence of uterine fibroids was estimated to range from 4.5% in the U.K to 9.8% in Italy. Additionally, the increasing geriatric population and growing pharmaceutical and healthcare sectors boost the market growth. According to the Population Reference Bureau in 2016, the Americas geriatric population is estimated to be more than double and reach about 98 million by 2060. However, factors such as low per capita healthcare expenditure, stringent government policies, and the presence of alternative treatments in the market are likely to restrain the market growth during the forecast period.

The Global Leuprolide Acetate Market is expected to grow at an approximate CAGR of 5.4% during the forecast period.
Segmentation

The global leuprolide acetate market is segmented on the basis of application, mode of administration, and end-user.

On the basis of application, the market is segmented into prostate cancer, precocious, uterine fibroid, and others. On the basis of the mode of administration, the market is categorized into intramuscular and subcutaneous. On the basis of end-user, the market is segmented into hospitals, clinics, medical institutes, and others.
Key players

The key players in the global leuprolide acetate market are TOLMAR Pharmaceuticals, Inc. (U.S.)

Varian Pharmed (Iran), avenit AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Sun Pharmaceutical Industries Ltd. (India), Livzon Pharmaceutical Group Co., Ltd. (China), Beijing Biote Pharmaceutical Co., Ltd (China), Soho-YImIng (China), AbbVie Inc. (U.S.), Sanofi (France), Astellas Pharma (Japan), Abbott (U.S), Merck KGaA (Germany), Pfizer Inc. (U.S.), and others.